Opportunity Information: Apply for RFA MH 25 181
This NIH funding opportunity (RFA-MH-25-181) invites applications for R21 exploratory/developmental research projects focused on how HIV-related neuroinflammation and HIV persistence within the central nervous system (CNS) influence each other, even when people have excellent control of the virus (typically meaning strong suppression with antiretroviral therapy). The core idea is that inflammation in the brain and spinal cord may help sustain viral reservoirs, while persistent virus or viral products in the CNS may, in turn, keep inflammatory pathways activated. By pushing for studies that look at this two-way, reinforcing relationship, the program aims to clarify mechanisms that contribute to HIV neuropathogenesis (how HIV leads to neurological injury or dysfunction) and to identify insights that could inform cure strategies, particularly those that must address the CNS as a distinct biological compartment.
The initiative emphasizes modern and innovative experimental approaches rather than traditional clinical intervention trials. Applicants are encouraged to use novel CNS cell systems and next-generation models that better mimic human brain biology, including organoid models and advanced single-cell technologies. In practice, this points toward studies that can dissect complex cellular ecosystems in the CNS, identify which cell types are driving or responding to inflammation, and determine where HIV persists at the level of individual cells or specific microenvironments. Using single-cell or similarly high-resolution methods can help distinguish rare infected or reservoir-harboring cells from broader inflammatory populations, and organoids or engineered co-culture systems can allow controlled testing of hypotheses about how glial cells, neurons, macrophage-lineage cells, and other CNS-associated cell types interact during suppressed infection.
Because this is an R21 mechanism, the funding is designed to support early-stage, high-impact, hypothesis-generating work, feasibility studies, and novel conceptual directions that may be too preliminary for larger R01-scale projects. The listing also specifies "Clinical Trial Not Allowed," meaning the application should not propose a prospective study in which human participants are assigned to receive an intervention to evaluate health-related outcomes. Research may still involve human-derived specimens or observational components depending on the full NIH definition and the specific FOA text, but applicants must ensure the proposed work does not meet NIH’s definition of a clinical trial.
From an administrative standpoint, the opportunity is a discretionary grant offered by the National Institutes of Health, with activity categories spanning education and health and CFDA numbers 93.242, 93.279, and 93.853. The original closing date is listed as November 8, 2024, and the opportunity was created on June 14, 2024. An award ceiling is not specified in the provided source data, and the expected number of awards is also not listed, so prospective applicants would typically confirm budget guidance and program expectations in the full announcement and related NIH policy pages for the R21 mechanism.
Eligibility is broad and includes many types of domestic organizations: state, county, and local governments; special districts; independent school districts; public housing authorities/Indian housing authorities; public and state-controlled institutions of higher education; private institutions of higher education; federally recognized tribal governments; tribal organizations that are not federally recognized; and a range of nonprofit organizations (with or without 501(c)(3) status) that are not institutions of higher education. It also allows for-profit organizations (other than small businesses) and small businesses, as well as an "other" category that can capture additional eligible entities. The announcement explicitly highlights additional eligible applicants, including Alaska Native and Native Hawaiian Serving Institutions, AANAPISIs, Hispanic-serving Institutions, Historically Black Colleges and Universities, Tribally Controlled Colleges and Universities, faith-based or community-based organizations, eligible federal agencies, U.S. territories or possessions, regional organizations, and non-U.S. (foreign) entities. Taken together, that eligibility language signals an interest in attracting a diverse set of institutions and research environments, potentially including groups that can contribute specialized model systems, unique technical platforms, or distinct perspectives on HIV-related neurological disease.
Overall, the grant’s purpose is to accelerate mechanistic discovery at the intersection of HIV persistence and neuroinflammation in the CNS under conditions of virologic suppression, using cutting-edge experimental systems and cellular-resolution analytic tools. The expected payoff is a clearer, more biologically grounded picture of how CNS reservoirs and inflammatory circuitry maintain each other, and how that feedback loop might be interrupted to reduce neurological harm and remove barriers to durable HIV remission or cure.Apply for RFA MH 25 181
- The National Institutes of Health in the education, health sector is offering a public funding opportunity titled "Mechanisms of Reciprocal Interactions between HIV Associated Neuroinflammation and CNS Persistence: Implications in HIV Neuropathogenesis and Cure (R21 Clinical Trial Not Allowed)" and is now available to receive applicants.
- Interested and eligible applicants and submit their applications by referencing the CFDA number(s): 93.242, 93.279, 93.853.
- This funding opportunity was created on 2024-06-14.
- Applicants must submit their applications by 2024-11-08. (Agency may still review applications by suitable applicants for the remaining/unused allocated funding in 2026.)
- Eligible applicants include: State governments, County governments, City or township governments, Special district governments, Independent school districts, Public and State controlled institutions of higher education, Native American tribal governments (Federally recognized), Public housing authorities/Indian housing authorities, Native American tribal organizations (other than Federally recognized tribal governments), Nonprofits having a 501 (c) (3) status with the IRS, other than institutions of higher education, Nonprofits that do not have a 501 (c) (3) status with the IRS, other than institutions of higher education, Private institutions of higher education, For-profit organizations other than small businesses, Small businesses, Others.
[Watch] Creating a grant proposal using the step-by-step wizard inside the applicant portal:
Frequently Asked Questions (FAQs)
What is the funding opportunity number and agency?
This opportunity is an NIH funding announcement identified as RFA-MH-25-181.
What type of NIH grant mechanism is this?
The announcement supports the R21 exploratory/developmental research mechanism, which is intended for early-stage, high-impact, hypothesis-generating studies, feasibility work, and novel research directions that may be too preliminary for larger projects.
What is the main scientific focus of this R21?
The focus is on understanding the two-way relationship between HIV-related neuroinflammation and HIV persistence in the central nervous system (CNS), especially in people with excellent viral control (typically strong suppression on antiretroviral therapy).
Why does the FOA emphasize a "two-way" relationship between neuroinflammation and HIV persistence?
The FOA is centered on the idea of a reinforcing feedback loop: inflammation in the CNS may help sustain HIV reservoirs, while persistent HIV (or viral products) within the CNS may keep inflammatory pathways activated. The goal is to clarify mechanisms that contribute to HIV neuropathogenesis and inform cure strategies that account for the CNS as a distinct compartment.
What does "CNS" mean in the context of this opportunity?
CNS refers to the central nervous system, including the brain and spinal cord, which the announcement treats as a distinct biological compartment relevant to HIV persistence and inflammation.
What is meant by "excellent control of the virus"?
In the provided description, this typically means strong suppression of HIV with antiretroviral therapy.
Does this opportunity fund traditional clinical intervention trials?
No. The announcement emphasizes modern and innovative experimental approaches rather than traditional clinical intervention trials.
Are clinical trials allowed under this FOA?
No. The listing specifies "Clinical Trial Not Allowed," meaning the application should not propose a prospective study in which human participants are assigned to receive an intervention to evaluate health-related outcomes.
Can projects still use human-derived samples or observational components?
The description notes that research may still involve human-derived specimens or observational components depending on the full NIH definition and the specific FOA text, but applicants must ensure the proposed work does not meet NIH's definition of a clinical trial.
What kinds of experimental approaches does the FOA encourage?
The opportunity encourages modern, innovative experimental approaches, including novel CNS cell systems and next-generation models that better mimic human brain biology. Examples mentioned include organoid models, engineered co-culture systems, and advanced single-cell technologies.
Why are organoids and advanced CNS models highlighted?
The provided description indicates these models can better mimic human brain biology and enable more controlled testing of hypotheses about interactions among CNS-associated cell types during suppressed infection.
Why does the FOA emphasize single-cell or high-resolution methods?
Single-cell or similarly high-resolution methods can help dissect complex CNS cellular ecosystems, identify which cell types are driving or responding to inflammation, and determine where HIV persists at the level of individual cells or microenvironments, including distinguishing rare infected or reservoir-harboring cells from broader inflammatory populations.
Which CNS cell types are specifically mentioned as relevant to study?
The description mentions glial cells, neurons, macrophage-lineage cells, and other CNS-associated cell types as examples of interacting populations that may be studied in organoids or engineered co-culture systems.
What is the overarching purpose of this funding opportunity?
The purpose is to accelerate mechanistic discovery at the intersection of HIV persistence and neuroinflammation in the CNS under conditions of virologic suppression, using cutting-edge experimental systems and cellular-resolution analytic tools.
How does this FOA connect to HIV cure strategies?
The program aims to generate insights that could inform cure strategies, particularly those that must address the CNS as a distinct compartment and overcome barriers posed by CNS reservoirs and inflammation.
What is meant by HIV neuropathogenesis in this announcement?
HIV neuropathogenesis is described as how HIV leads to neurological injury or dysfunction, and the FOA seeks mechanistic understanding of factors in the CNS that contribute to this process.
What is the application due date listed in the provided information?
The original closing date listed is November 8, 2024.
When was this opportunity created?
The opportunity was created on June 14, 2024.
Is there an award ceiling listed?
No award ceiling is specified in the provided source data.
Is the expected number of awards listed?
No. The expected number of awards is not listed in the provided information.
What should applicants do if they need budget or program expectation details?
Based on the provided description, applicants would typically confirm budget guidance and program expectations in the full announcement and related NIH policy pages for the R21 mechanism.
What type of grant is this from an administrative standpoint?
It is described as a discretionary grant offered by the National Institutes of Health.
What activity categories are associated with this opportunity?
The activity categories span education and health.
Which CFDA numbers are associated with this opportunity?
The provided information lists CFDA numbers 93.242, 93.279, and 93.853.
Who is eligible to apply?
Eligibility is broad and includes many types of domestic organizations, including state, county, and local governments; special districts; independent school districts; public housing authorities/Indian housing authorities; public and state-controlled institutions of higher education; private institutions of higher education; federally recognized tribal governments; tribal organizations that are not federally recognized; and nonprofit organizations (with or without 501(c)(3) status) that are not institutions of higher education.
Are for-profit organizations eligible?
Yes. The eligibility language includes for-profit organizations (other than small businesses) and also includes small businesses.
Are foreign (non-U.S.) entities eligible?
Yes. The announcement highlights that non-U.S. (foreign) entities are among the additional eligible applicants.
Are U.S. territories or possessions eligible?
Yes. U.S. territories or possessions are explicitly listed among additional eligible applicants.
Does the FOA encourage applications from specific institution types?
The announcement highlights additional eligible applicants including Alaska Native and Native Hawaiian Serving Institutions, AANAPISIs, Hispanic-serving Institutions, Historically Black Colleges and Universities, Tribally Controlled Colleges and Universities, faith-based or community-based organizations, eligible federal agencies, and regional organizations.
What is the main expected payoff of the research supported by this FOA?
The expected payoff is a clearer, more biologically grounded understanding of how CNS reservoirs and inflammatory circuitry maintain each other, and how that feedback loop might be interrupted to reduce neurological harm and remove barriers to durable HIV remission or cure.
Browse more opportunities from the same category: Education, Health
Next opportunity: Young Pacific Leaders – Alumni Roadshow
Previous opportunity: Cooperative Agreement for CESU-affiliated Partner with Chesapeake Watershed Cooperative Ecosystem Studies Unit
Applicant Portal:
Are you interested in learning about about how to apply for this government funding opportunity? You can create a free applicant account and receive instant access to our applicant portal that many business owners like you have benefited from.
Apply for RFA MH 25 181
Applicants also applied for:
Applicants who have applied for this opportunity (RFA MH 25 181) also looked into and applied for these:
| Funding Opportunity |
|---|
| Enhancing Mechanistic Research on Precision Probiotic Therapies (R61/R33 Clinical Trial Optional) Apply for PAR 24 238 Funding Number: PAR 24 238 Agency: National Institutes of Health Category: Education, Health Funding Amount: Case Dependent |
| Enhancing Mechanistic Research on Precision Probiotic Therapies (R33 Clinical Trial Optional) Apply for PAR 24 239 Funding Number: PAR 24 239 Agency: National Institutes of Health Category: Education, Health Funding Amount: Case Dependent |
| Mechanistic Studies to Investigate the Interrelationship Between Sleep and/or Circadian Rhythms and Substance Use Disorders (R01 Clinical Trials Not Allowed) Apply for RFA DA 25 045 Funding Number: RFA DA 25 045 Agency: National Institutes of Health Category: Education, Health Funding Amount: $200,000 |
| Mechanistic Studies to Investigate the Interrelationship Between Sleep and/or Circadian Rhythms and Substance Use Disorders (R01 Basic Experimental Studies with Humans Required) Apply for RFA DA 25 044 Funding Number: RFA DA 25 044 Agency: National Institutes of Health Category: Education, Health Funding Amount: $300,000 |
| Novel Preclinical Models of NeuroHIV in the cART Era (R61/R33 - Clinical Trial Not Allowed) Apply for RFA NS 24 035 Funding Number: RFA NS 24 035 Agency: National Institutes of Health Category: Education, Health Funding Amount: $600,000 |
| Combined Neuromodulation and Behavioral Treatment Algorithm Development for Stimulant Use Disorder (StUD) Enriched for Vulnerable Phenotype (U01 Clinical Trial Required) Apply for RFA DA 25 057 Funding Number: RFA DA 25 057 Agency: National Institutes of Health Category: Education, Health Funding Amount: $500,000 |
| D-START: Data Science Track Award for Research Transition (D/START) (R03-Clinical Trial Optional) Apply for PAS 24 242 Funding Number: PAS 24 242 Agency: National Institutes of Health Category: Education, Health Funding Amount: $1,000,000 |
| Translational Resource Centers to Build Bridges Between Substance Use Epidemiology/Etiology and Prevention Intervention Research (U24 Clinical Trials Not Allowed) Apply for RFA DA 25 085 Funding Number: RFA DA 25 085 Agency: National Institutes of Health Category: Education, Health Funding Amount: $350,000 |
| National Cancer Institute Youth Enjoy Science Research Education Program (R25 Clinical Trial Not Allowed) Apply for RFA CA 24 026 Funding Number: RFA CA 24 026 Agency: National Institutes of Health Category: Education, Health Funding Amount: $400,000 |
| Successor-in-Interest (Type 6 Parent Clinical Trial Optional) Apply for PA 24 253 Funding Number: PA 24 253 Agency: National Institutes of Health Category: Education, Health Funding Amount: Case Dependent |
| Device Based Treatments for Substance Use Disorders (UG3/UH3 Clinical Trial Optional) Apply for PAR 25 023 Funding Number: PAR 25 023 Agency: National Institutes of Health Category: Education, Health Funding Amount: $500,000 |
| Translating Socioenvironmental Influences on Neurocognitive Development and Addiction Risk (TranSINDA) (U01 Clinical Trial Not Allowed) Apply for RFA DA 25 037 Funding Number: RFA DA 25 037 Agency: National Institutes of Health Category: Education, Health Funding Amount: Case Dependent |
| Translating Socioenvironmental Influences on Neurocognitive Development and Addiction Risk (TranSINDA) (U24 Clinical Trial Not Allowed) Apply for RFA DA 25 038 Funding Number: RFA DA 25 038 Agency: National Institutes of Health Category: Education, Health Funding Amount: Case Dependent |
| Maximizing Opportunities for Scientific and Academic Independent Careers (MOSAIC) Organizational Research Education Award to Promote Diversity (UE5 - Clinical Trial Not Allowed) Apply for PAR 24 224 Funding Number: PAR 24 224 Agency: National Institutes of Health Category: Education, Health Funding Amount: Case Dependent |
| RNA Modifications Driving Oncogenesis (RNAMoDO; U01 Clinical Trial Not Allowed) Apply for RFA CA 24 029 Funding Number: RFA CA 24 029 Agency: National Institutes of Health Category: Education, Health Funding Amount: Case Dependent |
| NCI Outstanding Investigator Award (R35) Apply for PAR 15 342 Funding Number: PAR 15 342 Agency: National Institutes of Health Category: Education, Health Funding Amount: $600,000 |
| AIDS-Science Track Award for Research Transition (R03) Apply for PA 15 290 Funding Number: PA 15 290 Agency: National Institutes of Health Category: Education, Health Funding Amount: $100,000 |
| Planning for Regional Centers of Research Excellence in Non-communicable Diseases in Low and Middle Income Countries (P20) Apply for RFA CA 15 007 Funding Number: RFA CA 15 007 Agency: National Institutes of Health Category: Education, Health Funding Amount: $200,000 |
| Research on Informal and Formal Caregiving for Alzheimer's Disease (R01) Apply for PAR 15 348 Funding Number: PAR 15 348 Agency: National Institutes of Health Category: Education, Health Funding Amount: Case Dependent |
| Research on Informal and Formal Caregiving for Alzheimer's Disease (R21) Apply for PAR 15 351 Funding Number: PAR 15 351 Agency: National Institutes of Health Category: Education, Health Funding Amount: $200,000 |
Grant application guides and resources
It is always free to apply for government grants. However the process may be very complex depending on the funding opportunity you are applying for. Let us help you!
Apply for Grants
Inside Our Applicants Portal
Access Applicants Portal
- Grants Repository - Access current and historic funding opportunities with ease. Thousands of funding opportunities are published every week. We can help you sort through the database and find the eligible ones to apply for.
- Applicant Video Guides - The grant application process can be challenging to follow. We can help you with intuitive video guides to speed up the process and eliminate errors in submissions.
- Grant Proposal Wizard - We have developed a network of private funding organizations and investors across the United States. We can reach out and submit your proposal to these contacts to maximize your chances of getting the funding you need.
Premium leads for funding administrators, grant writers, and loan issuers
Thousands of people visit our website for their funding needs every day. When a user creates a grant proposal and files for submission, we pass the information on to funding administrators, grant writers, and government loan issuers.
If you manage government grant programs, provide grant writing services, or issue personal or government loans, we can help you reach your audience.
Learn More
Request more information:
Would you like to learn more about this funding opportunity, similar opportunities to "RFA MH 25 181", eligibility, application service, and/or application tips? Submit an inquiry below:
Don't forget to subscribe to our grant alerts mailing list to receive weekly alerts on new and updated grant funding opportunities like this one in your email.